The Zacks Analyst Blog Highlights Amazon.com, Stryker, Lam Research and ImmuCell

For Immediate ReleaseChicago, IL – December 4, 2024 – Zacks.com announces the list of Stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. AMZN, Stryker Corp. SYK, Lam Research Corp. LRCX and ImmuCell Corp. ICCC.Here are highlights from Tuesday’s Analyst Blog:Top Research Reports for Amazon, Stryker and Lam ResearchThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc., Stryker Corp. and Lam Research Corp., as well as a micro-cap stock, ImmuCell Corp. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Amazon’s shares have outperformed the Zacks Internet – Commerce industry over the past year (+45.5% vs. +40.8%). The Zacks analyst believes that strengthening AWS services portfolio and its growing adoption rate have contributed well to the stock's performance. Ultrafast delivery services, expanding content portfolio and Amazon’s expanding global presence have also benefited the company. Deepening focus on generative AI is a major plus.However, macroeconomic challenges remain headwinds. Rising transportation and fulfillment center costs are concerns.(You can read the full research report on Amazon here >>>)Stryker’s shares have outperformed the Zacks Medical - Products industry over the past year (+33.9% vs. +20.9%). The Zacks analyst believes that strong international sales, ongoing procedural recovery and a strong order book for capital equipment bode well for the company. Strong customer demand is a major plus.Yet, inflationary pressure and supply-chain challenges continue to plague Stryker. Stiff competition in the MedTech space remains a headwind.(You can read the full research report on Stryker here >>>)Shares of Lam Research have underperformed the Zacks Electronics – Semiconductors industry over the past year (+10.6% vs. +45.7%). Per the Zacks analyst, global spending on mature nodes is likely to be flat year over year. Growing tensions between the United States and China remain major concerns and have contributed to the stocks underperformance this year.However, the company is riding on its strength across 3D DRAM and advanced packaging technologies. Also, rebound in the system business owing to improving memory spending is a positive.(You can read the full research report on Lam Research here >>>)Immucell’s shares have underperformed the Zacks Medical - Products industry over the last six months (-3.9% vs. +11.9%). The Zacks analyst believes that the company has been hindered by high production costs and increased depreciation from expanded facilities. High customer concentration, shareholder dilution and competition from giants like Zoetis and Merck also pose risks.Yet, robust customer demand for First Defense has been a key driver of sales growth. The remediation of contamination issues and investments in capacity expansion have positioned the company to stabilize output at higher levels.(You can read the full research report on Immucell here >>>)Why Haven't You Looked at Zacks' Top Stocks?Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.Today you can access their live picks without cost or obligation.See Stocks Free >>Media ContactZacks Investment Research800-767-3771 ext. 9339support@zacks.comhttps://www.zacks.comPast performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report ImmuCell Corporation (ICCC): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks